转移性去势抵抗性前列腺癌18F-NaF PET/CT骨闪烁现象的量化研究
结果显示,CYP17A1抑制剂治疗患者中61%(14/23)出现骨闪烁,而恩扎卢胺组6例均未出现;第6周平均SUV升高与PFS延长相关(HR=0.58,p=0.02)。
要点
- CYP17A1抑制剂治疗mCRPC患者中61%出现NaF PET骨闪烁,恩扎卢胺组未见。
- 第6周平均SUV升高与PFS延长相关(HR=0.58,p=0.02)。
- 骨闪烁需与真性进展鉴别,以免误判疗效。
核心结论
- CYP17A1抑制剂治疗前6周内61%的mCRPC患者出现NaF PET骨闪烁。
- 出现骨闪烁的患者提示PFS favorable。
研究设计与样本
- 于基线、第6周和第12周行18F-NaF PET/CT扫描,提取全局SUV和病灶iSUV。
主要发现
- 总SUV对骨闪烁检测最敏感,在14/23(61%)接受CYP17A1抑制剂的患者中识别出骨闪烁。
- 6例接受恩扎卢胺治疗的患者均未识别出骨闪烁。
- 新病灶的出现不能解释SUV指标的初始升高。
- 骨闪烁阳性患者中,中位72%(范围0-100%)的病灶显示总iSUV闪烁。
- 第6周平均SUV升高与PFS延长相关(HR=0.58,p=0.02)。
关键数值与推荐
- 骨闪烁定义为第6周SUV指标或病灶数量增加,随后第12周下降。
- 时间点间指标差异采用Wilcoxon检验比较。
- 全局指标与PFS的关系采用Cox比例风险回归分析。
临床怎么用
- 在CYP17A1抑制剂治疗早期(前6周)需注意骨闪烁现象,避免误判为疾病进展。
- NaF PET骨闪烁特征可用于指导治疗评估时间安排,以区分骨闪烁与真性进展。
局限性
- 恩扎卢胺组仅6例,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone flare has been observed on 99mTc-MDP bone scans of patients with metastatic castration-resistant prostate cancer (mCRPC). This exploratory study investigates bone flare in mCRPC patients receiving androgen receptor (AR) inhibitors using 18F-NaF PET/CT. METHODS: Twenty-nine mCRPC patients undergoing AR-inhibiting therapy (abiraterone, orteronel, enzalutamide) received NaF PET/CT scans at baseline, week 6, and week 12 of treatment. SUV metrics were extracted globally for each patient (SUV) and for each individual lesion (iSUV). Bone flare was defined as increasing SUV metrics or lesion number at week 6 followed by subsequent week 12 decrease. Differences in metrics across timepoints were compared using Wilcoxon tests. Cox proportional hazard regression was conducted between global metrics and progression-free survival (PFS). RESULTS: Total SUV was most sensitive for flare detection and was identified in 14/23 (61%) patients receiving CYP17A1-inhibitors (abiraterone, orteronel), and not identified in any of six patients receiving enzalutamide. The appearance of new lesions did not account for initial increases in SUV metrics. iSUV metrics followed patient-level trends: bone flare positive patients showed a median of 72% (range: 0-100%) of lesions with total iSUV flare. Increasing mean SUV at week 6 correlated with extended PFS (HR = 0.58, p = 0.02). CONCLUSION: NaF PET bone flare was present on 61% of mCRPC patients in the first 6 weeks of treatment with CYP17A1-inhibitors. Characterization provided in this study suggests favorable PFS in patients showing bone flare. This characterization of NaF flare is important for guiding treatment assessment schedules to better distinguish between patients showing bone flare and those truly progressing, and should be performed for all emerging mCRPC treatments and imaging agents.
引用
- Weisman AJ, Harmon SA, Perk TG, et al. Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30413807. doi:10.1038/s41391-018-0110-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。